Univariate analysis comparing patient demographic characteristics, pathologic features and stage between colorectal cancers staged in the 2 years before the COVID-19 pandemic and in the first year of the pandemic
| Variable | No. (%)of cases* | Standardized difference | Stochastic dominance | OR (95% CI) | |
|---|---|---|---|---|---|
| 2 years before pandemic n = 455 | First year of pandemic n = 193 | ||||
| No. of cases per 30 d, mean | 18.7 | 15.9 | NA | ||
| Age, median (IQR), yr | 72 (64–80) | 73 (61–79) | 0.040 | – | NA |
| Sex | |||||
| Female | 204 (44.8) | 90 (46.6) | 0.036 | 0.491 | 1.08 (0.77–1.51) |
| Male | 251 (55.2) | 103 (53.4) | 0.93 (0.66–1.30) | ||
| Screening-detected | |||||
| No | 376 (83.2) | 167 (87.0) | 0.107 | 0.481 | 1.35 (0.84– 2.18) |
| Yes | 76 (16.8) | 25 (13.0) | 0.74 (0.45–1.20) | ||
| NA | 3 | 1 | |||
| Histologic subtype | |||||
| Adenocarcinoma | 357 (78.6) | 152 (78.8) | 0.111 | – | 1.01 (0.67–1.53) |
| Mucinous adenocarcinoma | 42 (9.3) | 13 (6.7) | 0.70 (0.37–1.34) | ||
| Other | 55 (12.1) | 28 (14.5) | 1.23 (0.75–2.01) | ||
| NA | 1 | 0 | |||
| Tumour size, median (IQR), cm | 4.5 (3.0–6.0) | 4.3 (3.3–6.0) | –0.025 | – | NA |
| Lymphovascular invasion | 247 (54.3) | 110 (57.0) | 0.055 | 0.514 | 1.12 (0.79–1.57) |
| Perineural invasion | 113 (24.8) | 50 (25.9) | 0.025 | 0.506 | 1.06 (0.72–1.56) |
| Positive margin | 57 (12.5) | 19 (9.8) | 0.085 | 0.487 | 0.76 (0.44–1.32) |
| Tumour perforation | 16 (3.5) | 8 (4.1) | 0.033 | 0.504 | 1.18 (0.50–2.80) |
| Stage | |||||
| I | 102 (22.5) | 35 (18.1) | – | 0.532 | NA |
| II | 164 (36.2) | 66 (34.2) | |||
| III | 150 (33.1) | 79 (40.9) | |||
| IV | 37 (8.2) | 13 (6.7) | |||
| NA | 2 | 0 | |||
Note: CI = confidence interval, IQR = interquartile range, NA = not applicable, OR = odds ratio.
↵* Except where noted otherwise.